Biogen is addressing profitability concerns and a lack of top-line growth. Read more to see an overview and analysis of BIIB ...

Biogen's Alzheimer therapy, Leqembi, is gaining traction with Q1'24 sales of $19m, nearly tripling Q4 revenues. Read my ...

One of the best ways to keep your portfolio safe while generating consistent income is in safe, dividend-paying retirement stocks at 52-week lows. It’s even better if you’re buying into a reputable ...

In the preceding three months, 27 analysts have released ratings for Biogen (NASDAQ:BIIB), presenting a wide array of ...

It was a busy week in the biotech sector with earnings reports from bigwigs Biogen BIIB and Bristol Myers Squibb BMY. Other ...

Biogen shares gained ground before market open Wednesday, after the company reported first-quarter profit that beat analysts’ ...

Prologis, Inc. (NYSE:PLD) is one of the most promising stocks to buy before they take off. Other such stocks include Li Auto ...

Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while ...

The Nasdaq composite has historically had a high correlation with the S&P 500. The two indexes even share common components, ...

Another one of our AI-picked winners is soaring after smashing top and bottom-line estimates for its Q1 earnings report this morning. After more than doubling EP ...